The effect of Thalidomide on sputum biomarkers in IPF cough

• Research type

  Research Study

• Full title

  The effect of Thalidomide on sputum biomarkers in IPF cough.

• IRAS ID

  33170

• Contact name

  Gisli Jenkins

• Eudract number

  2010-023828-24

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  IPF is characterized by injury to the lung epithelial cells and abnormal tissue repair which results in respiratory failure. Onset of symptoms is usually gradual, with shortness of breath, the most prominent and disabling symptom, in addition to dry cough which is often refractory to anti-tussive agents. It is common in older people, male gender and residents living in the Northern and Western regions of UK. The prognosis of people with IPF is similar to that of stage 1 and 2 Non-small cell Lung Cancer, in that the median survival from diagnosis is less than 3 years and people die on average 7 years prematurely. Current best estimates of incidence are 7 per 100,000 person-years or approximately 4500 new cases of IPF each year in UK.IPF now represents important public health problem in UK with the burden of disease being similar to conditions such as ovarian and renal cancer.At present there is no definitive treatment. The causative molecular pathways are poorly understood. This study will use thalidomide as treatment of cough and measure change in biomarkers at the beginning and end of study. We aim to identify candidate pathways that may be important to consider in the therapeutic interventions in future.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  10/H0405/102

• Date of REC Opinion

  7 Jan 2011

• REC opinion

  Further Information Favourable Opinion